<- Go Home
OptiNose, Inc.
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.
Market Cap
$97.2M
Volume
63.1K
Cash and Equivalents
$72.9M
EBITDA
-$15.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$74.1M
Profit Margin
90.53%
52 Week High
$20.02
52 Week Low
$4.81
Dividend
N/A
Price / Book Value
-1.58
Price / Earnings
-3.59
Price / Tangible Book Value
-1.58
Enterprise Value
$153.9M
Enterprise Value / EBITDA
-11.83
Operating Income
-$15.8M
Return on Equity
37.23%
Return on Assets
-9.97
Cash and Short Term Investments
$72.9M
Debt
$129.6M
Equity
-$61.4M
Revenue
$81.9M
Unlevered FCF
$1.8M
Sector
Pharmaceuticals
Category
N/A